Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
EverCommerce Q4 2025 Earnings Call - AI-First Push and ZyraTalk Drive Product Momentum
EverCommerce closed 2025 with steady top-line growth, expanded margins, and a clear strategic pivot to AI-first productization. Q4 revenue of $151.2 million beat guidance, adjusted EBITDA held at $44....
- Q4 2025 revenue was $151.2 million, up 5.2% year over year, beating the midpoint of guidance.
- Q4 adjusted EBITDA was $44.2 million, flat year over year, yielding a 29.2% adjusted EBITDA margin.
- Adjusted gross profit for Q4 was $117.0 million, with an adjusted gross margin of 77.5%.
- +17 more takeaways
Ascend Wellness Holdings Q4 2025 Earnings Call - Densification and cost cuts hold margins amid relentless price compression
Ascend closed 2025 with a playbook that reads like damage control and discipline. Revenue fell to $500.6 million for the year, but management leaned into densification, verticalization, and a $30 mill...
- Q4 2025 revenue $120.5 million, down 3.4% sequentially; full-year 2025 revenue $500.6 million, down 10.9% year-over-year.
- Q4 Adjusted EBITDA $30.2 million, margin 25.1% (up 20 basis points sequentially); full-year Adjusted EBITDA $116.9 million, margin 23.4%.
- Retail first strategy: retail made up ~70.5% of Q4 revenue; retail sales $85.0 million in Q4, up 1.4% quarter-over-quarter.
- +12 more takeaways
Capricor Therapeutics Q4 2025 Earnings Call - BLA Accepted, PDUFA Aug 22 2026
Capricor walked into 2026 with the outcome every biotech CFO and patient advocate prays for. The FDA has accepted the companys Class 2 BLA resubmission for Deramiocel and set a PDUFA target action dat...
- FDA accepted Capricors Class 2 BLA resubmission for Deramiocel, PDUFA date set for August 22, 2026.
- HOPE-3 pivotal trial (n=106) met primary endpoint Performance of the Upper Limb and all Type I error controlled secondaries.
- Left ventricular ejection fraction showed a 91 percent slowing of disease progression overall, with a p value of 0.01 in the cardiomyopathy subgroup.
- +16 more takeaways
Silvaco Q4 FY2025 Earnings Call - FTCO AI traction and Mixel IP turbocharge bookings, targeting profitability
Silvaco closed Q4 FY2025 with a clear inflection: bookings and revenue landed near the top of guidance, driven by a faster-than-expected commercial ramp of FTCO, the companys AI-driven process develop...
- Q4 bookings were $18.3 million, at the high end of guidance; Q4 revenue was also $18.3 million, above guidance.
- TCAD delivered a large sequential rebound: bookings rose 70% to $9.2 million and revenue rose 34% to $8.7 million, driven by FTCO adoption.
- FTCO, Silvacos AI-driven process development platform, signed a second customer in Asia in Q4, and management says adoption is accelerating beyond memory use cases.
- +12 more takeaways
Atlanticus Holdings Corporation Fourth Quarter 2025 Earnings Call - Mercury Deal Doubles Balance Sheet, Integration Ahead of Plan
Atlanticus closed a transformational 2025 by completing the Mercury Financial acquisition, roughly doubling its balance sheet to about $7 billion and adding 1.3 million customers. Management says inte...
- Mercury acquisition completed in 2025, roughly doubling Atlanticus’s balance sheet to about $7 billion and adding more than 1.3 million customers.
- Management says Phase one of Mercury portfolio repositioning is complete and is performing better than modeled, with additional phases continuing through 2026.
- Atlanticus acquired a $165 million retail credit portfolio during the quarter, strengthening its second-look point-of-sale position.
- +15 more takeaways
Allogene Therapeutics Q4 2025 Earnings Call - Data-Driven Year Ahead, ALPHA3 MRD Readout in April and ALLO-329 PoC in June
Allogene enters 2026 with a tight, evidence-first playbook: an April interim MRD readout from ALPHA3 that could validate allogeneic CAR T as frontline consolidation in large B-cell lymphoma, and a Jun...
- April 2026: interim MRD futility analysis from ALPHA3 will report MRD clearance in 24 patients, 12 per arm, plus early safety; company has set an internal meaningful threshold at a 25% to 30% absolute delta in MRD conversion.
- June 2026: proof of concept readout expected for ALLO-329 in the phase 1 RESOLUTION trial, with translational and early clinical signals from dose level 1.
- ALLO-329 is engineered as a dual CD19/CD70 allogeneic CAR T with Dagger technology, designed to enable meaningful expansion and persistence at low, or possibly no, conventional lymphodepletion.
- +12 more takeaways
ServiceTitan Fourth Quarter Fiscal Year 2026 Earnings Call - Max pilot promises step-change in AI-driven monetization
ServiceTitan closed FY26 with $961m in revenue, a $1bn-plus run rate milestone, stronger margins, and a clear pivot: turn the platform into an agentic operating system via Max. Management leaned hard ...
- Company exceeded $1 billion annualized revenue run rate, finishing FY26 with $961m in revenue, up 24% year-over-year for the full year.
- Q4 FY26 results: GTV $19.8bn (up 16% yoy), total revenue $254m (up 21% yoy), subscription revenue $192m (up 23% yoy).
- Platform gross margin improved to 80% in Q4, up ~330 basis points year-over-year; total gross margin 73.8%, up ~360 basis points.
- +17 more takeaways
KinderCare Learning Fourth Quarter 2025 Earnings Call - Enrollment Slump Forces Lower 2026 EBITDA Guide
Tom Wyatt returned as CEO in December and opened the call with a blunt assessment: execution slipped and enrollment fell short of expectations. Q4 and full-year 2025 results were propped up by an extr...
- Tom Wyatt returned as CEO in December and said the company fell short on consistency and execution, particularly at the center level.
- Q4 2025 revenue was $688 million, up 6% year-over-year, but that includes a $45 million contribution from a 53rd week; on a comparable basis revenue was essentially flat.
- Q4 adjusted EBITDA was $68 million, which included approximately $12 million from the extra week; adjusted EPS was $0.12.
- +12 more takeaways
Pixelworks FY2025 Earnings Call - Shanghai Sale Recasts Pixelworks as Cash-Rich, Asset-Light Licensing Company
Pixelworks used a January 6, 2026 closing of its Shanghai semiconductor subsidiary sale to pivot from a capital-intensive China hardware business to a lean, global technology licensing company centere...
- Pixelworks closed sale of its Shanghai semiconductor subsidiary on January 6, 2026, receiving approximately $51 million in net cash proceeds.
- Had the sale and prior Q4 transactions closed before year end, the company would have entered 2026 with about $62 million in cash; management now expects roughly $58 million as of March 31 after transaction costs, severances, and bonuses.
- Continuing operations revenue for fiscal 2025 was about $690,000, comprised entirely of TrueCut Motion platform and motion grading services; the semiconductor business is presented as discontinued operations.
- +12 more takeaways
Adobe Q1 FY2026 Earnings Call - AI-driven MAU surge offsets stock decline as CEO announces transition
Adobe opened FY2026 with a clean, AI-flavored quarter. Revenue hit $6.4 billion, up 11% in constant currency, non-GAAP EPS rose 19% to $6.06, and total ARR reached $26.06 billion. The company is seein...
- CEO succession announced: Shantanu Narayen will transition from CEO over the coming months and remain Chair to support the handoff.
- Q1 top line: Revenue $6.40 billion, up 12% reported and 11% in constant currency.
- Profitability: GAAP EPS $4.60, non-GAAP EPS $6.06 (up 19% YoY); GAAP operating margin 37.8%, non-GAAP operating margin 47.4%.
- +13 more takeaways